April 30 (Reuters) - Genmab A/S:
* REG-CHMP ISSUES POSITIVE OPINION RECOMMENDING SUBCUTANEOUS FORMULATION OF DARATUMUMAB FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA
* GENMAB A/S - OPINION BASED ON DATA FROM PHASE III COLUMBA AND PHASE II PLEIADES STUDIES COPENHAGEN, DENMARK Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.